[{"orgOrder":0,"company":"Neuramedy","sponsor":"Bioasis","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Tomaralimab","moa":"TLR2","graph1":"Neurology","graph2":"Preclinical","graph3":"Neuramedy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Neuramedy \/ Bioasis","highestDevelopmentStatusID":"4","companyTruncated":"Neuramedy \/ Bioasis"}]

Find Clinical Drug Pipeline Developments & Deals for Tomaralimab

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2.

                          Brand Name : NM-101

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 10, 2022

                          Lead Product(s) : Tomaralimab

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Bioasis

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank